Amgen to terminate participation in co-development and commercialization of brodalumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Amgen (AMGN) Announces Termination of Brodalumab Agreement with AstraZeneca (AZN)
May 26, 2015 6:56 AM EDTAmgen (NASDAQ: AMGN) announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (NYSE: AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and... More
